Anti-CDKN2B antibody (50-138) [PTR2192] (STJA0006247)

SKU:
STJA0006247

Current Stock:
Host: Mouse
Applications: WB/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Cyclin-dependent kinase 4 inhibitor B (50-138) is suitable for use in Western Blot and ELISA research applications.
Clonality: Monoclonal
Clone ID: PTR2192
Conjugation: Unconjugated
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CDKN2B
Gene ID: 1030
Uniprot ID: CDN2B_HUMAN
Immunogen Region: 50-138
Specificity: This antibody detects endogenous levels of p15 INK (PTR2192) at Human. The antibody was also Predict react with Mouse;Rat
Immunogen: Synthesized peptide derived from human p15 INK (PTR2192) AA range: 50-138
Tissue Specificity Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines.
Function Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.
Protein Name Cyclin-Dependent Kinase 4 Inhibitor B
Multiple Tumor Suppressor 2
Mts-2
P14-Ink4b
P15-Ink4b
P15ink4b
Database Links Reactome: R-HSA-2173796
Reactome: R-HSA-2559580
Reactome: R-HSA-2559582
Reactome: R-HSA-2559585
Reactome: R-HSA-69231
Cellular Localisation Cytoplasm
Also Found In The Nucleus
Alternative Antibody Names Anti-Cyclin-Dependent Kinase 4 Inhibitor B antibody
Anti-Multiple Tumor Suppressor 2 antibody
Anti-Mts-2 antibody
Anti-P14-Ink4b antibody
Anti-P15-Ink4b antibody
Anti-P15ink4b antibody
Anti-CDKN2B antibody
Anti-MTS2 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance